Amcad Biomed (ROCO:4188) Moat Score: 0/10 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
53 GF Score
Price NT$9.45
GF Value NT$9.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Amcad Biomed Moat Score?

Amcad Biomed has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Amcad Biomed has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Amcad Biomed might have No Moat - No discernible moat.

Amcad Biomed  (ROCO:4188) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Amcad Biomed Moat Score Related Terms

ROCO:4188
53GF Score
Amcad Biomed Corp ROCO:4188
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10. GuruFocus considers Amcad Biomed to be Fairly Valued.

Key valuation signals for ROCO:4188:

  • Moat Score: 0
  • GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score

Get the complete analysis for ROCO:4188

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$9.45
Price
NT$9.10
GF Value